Browsing by Author "Garrido, M."
Now showing 1 - 7 of 7
Results Per Page
Sort Options
- ItemConsultas ambulatorias pediátricas atendidas en el Servicio de Urgencia de un hospital universitario(2014) Lara Hernández, Bárbara Alejandra; Aguilera Fuenzalida, Pablo René; Garrido, M.; Hirsch Birn, Tamara Eugenia; Swadron, S.; Saldías Peñafiel, Fernando
- ItemMetastatic neuroendocrine carcinoma of the colon: response to standard colorectal therapy(2013) Acevedo Claros, Francisco Nicolás; Otarola, C.; Valbuena Mora, José Rafael; Garrido, M.
- ItemModulation of glycosyltransferase ST6Gal-I in gastric cancer-derived organoids disrupts homeostatic epithelial cell turnover(2020) Alexander, K. L.; Serrano Honeyman, Carolina; Chakraborty, A.; Nearing, M.; Council, L. N.; Riquelme Pérez, Arnoldo; Garrido, M.; Bellis, S. L.; Smythies, L. E.; Smith, P. D.
- ItemNeoadjuvant chemoradiation therapy for borderline pancreatic adenocarcinoma: report of two cases(2013) Galindo, J.; Gabrielli Nervi, Mauricio; Guerra, J. F.; Cassina, J. C.; Garrido, M.; Jarufe Cassis, Nicolás; Borghero Ríos, Yerko Orestes; Madrid Arenas, Jorge; Zoroquiain Vélez, José Pablo; Roa Strauch, Juan Carlos Enrique; Martínez, J.
- ItemOptimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry(SPRINGER INTERNATIONAL PUBLISHING AG, 2020) Viudez, A.; Carmona Bayonas, A.; Gallego, J.; Lacalle, A.; Hernandez, R.; Cano, J. M.; Macias, I; Custodio, A.; Martinez de Castro, E.; Sanchez, A.; Iglesia, L.; Reguera, P.; Visa, L.; Azkarate, A.; Sanchez Canovas, M.; Mangas, M.; Limon, M. L.; Martinez Torron, A.; Asensio, E.; Ramchandani, A.; Martin Carnicero, A.; Hurtado, A.; Cerda, P.; Garrido, M.; Sanchez Bayonas, R.; Serrano, R.; Jimenez Fonseca, P.; AGAMENON Study GrpBackground The optimal duration of first-line chemotherapy for patients with advanced gastric cancer is unknown. Diverse clinical trials have proposed different strategies including limited treatment, maintenance of some drugs, or treatment until progression. Method The sample comprises patients from the AGAMENON multicenter registry without progression after second evaluation of response. The objective was to explore the optimal duration of first-line chemotherapy. A frailty multi-state model was conducted. Results 415 patients were divided into three strata: discontinuation of platinum and maintenance with fluoropyrimidine until progression (30%, n = 123), complete treatment withdrawal prior to progression (52%, n = 216), and full treatment until progression (18%, n = 76). The hazard of tumor progression decreased by 19% per month with the full treatment regimen. However, we found no evidence that fluoropyrimidine maintenance (hazard ratio [HR] 1.07, confidence interval [CI] 95%, 0.69-1.65) worsened progression-free survival (PFS) with respect to treatment until progression. Predictive factors for PFS were ECOG performance status, >= 3 metastatic sites, prior tumor response, and bone metastases. Toxicity grade 3/4 was more common in those who continued the full treatment until progression vs fluoropyrimidine maintenance (16% vs 6%). Conclusion The longer duration of the full initial regimen exerted a protective effect on the patients of this registry. Platinum discontinuation followed by fluoropyrimidine maintenance yields comparable efficacy to treatment up to PD, with a lower rate of serious adverse events.
- ItemProlonged survival of a woman with lung cancer diagnosed and treated with chemotherapy during pregnancy - Review of cases reported(ELSEVIER IRELAND LTD, 2008) Garrido, M.; Clavero, J.; Huete, A.; Sanchez, C.; Solar, A.; Alvarez, M.; Orellana, E.Lung cancer is the most common cause of cancer death in women in the US, diagnosis during pregnancy is rare and has been reported 34 times. We report a case of a 34-year-old woman with stage III locally advanced lung cancer diagnosed during the 27th week of pregnancy. Chest X-ray and thorax MRI revealed a 9 cm x 7 cm mass in the upper right lung lobe. CT guided FNA biopsy indicated adenocarcinoma. Neoadjuvant chemotherapy was administered with vinorelvine (Navetbine (R)) and cisplatin for three cycles with partial response. At 39 weeks, she delivered a healthy baby. Right upper lobectomy with complete lymphadenectomy was performed 3 weeks later. Final pathology was reported as an adenocarcinoma of 7.5 cm x 6.2 cm with involvement of 16/30 lymph nodes. She received three additional cycles of chemotherapy and radiotherapy. Follow-up with CT scan after 11 months did not show recurrence. (C) 2007 Elsevier Ireland Ltd. Ail rights reserved.
- ItemSíndrome de HELLP normotensivo : caso clínico(2013) Garrido, M.; Carvajal C., Jorge A.